Status:
COMPLETED
Henagliflozin Reducing Infarct Size After Priamry PCI in Patients With ST Segment Elevation Myocardial Infarction
Lead Sponsor:
Qian geng
Conditions:
Myocardial Infarction
Heart Failure
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
This Randomized controlled intervention study recruited patients diagnosed with ST-segment elevation myocardial infarction (STEMI). A total of 240 patients were enrolled in either Henagliflozin group ...
Detailed Description
This Randomized controlled intervention study recruited patients diagnosed with ST-segment elevation myocardial infarction (STEMI) who were scheduled to undergo emergency percutaneous coronary interve...
Eligibility Criteria
Inclusion
- STEMI patients with clear diagnosis: ischemic chest pain lasting for more than 30 minutes and adjacent to two or more leads of ST Segment elevation (limb lead ≥ 0.1mV, chest lead ≥ 0.2mV) with or without elevated myocardial enzyme levels;
- Chest pain lasting less than 12 hours;
- Age range from 18 to 80 years old;
- Plans to undergo primary PCI ;
- Informed consent form
Exclusion
- Mechanical complications;
- Cardiogenic shock;
- Experienced myocardial infarction within 6 months;
- Aortic dissection;
- Suffering from malignant tumors, severe liver and kidney failure, respiratory failure, or other short-term progressive diseases that researchers believe cannot be included
- Urinary system infection
Key Trial Info
Start Date :
July 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2025
Estimated Enrollment :
248 Patients enrolled
Trial Details
Trial ID
NCT06187727
Start Date
July 1 2023
End Date
October 1 2025
Last Update
December 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA general hospital
Beijing, Beijing Municipality, China, 100853